If validated prospectively, the findings could be ‘transformative’ for patients with no current medical options.
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with additional cardiovascular risk factors, can significantly reduce heart ...
The Brighterside of News on MSN1d
First of its kind drug significantly reduces heart attacks and strokesA recently approved drug has shown promise in reducing heart attacks and strokes in patients with type 2 diabetes and kidney disease. This medication, a sodium-glucose cotransporter (SGLT) inhibitor, ...
Sotagliflozin, a drug recently approved by the Food and Drug Administration to treat type 2 diabetes and kidney disease with ...
Sotagliflozin, recently approved by the FDA for treating type 2 diabetes and kidney disease in patients with cardiovascular ...
Sotagliflozin, a drug for diabetes and kidney disease, offers significant protection against heart attacks and strokes by ...
The results showed that people who took sotagliflozin had a 23% lower risk of heart attacks, strokes, and death from ...
An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help ...
Both SGLT2 inhibitors and GLP-1s lowered moderate or severe COPD exacerbation risk vs. DPP-4 inhibitors. Weight loss and SGLT2 inhibitors’ glucosuria effect may explain the findings. Sodium ...
as it has not been observed in trials of selective SGLT2 inhibitors." "These results demonstrate a new mechanism of action -- combined blockade with sotagliflozin of the SGLT1 receptors found in ...
Less than 5% of hospitalized adults with type 2 diabetes received an SGLT2 inhibitor or GLP-1 before being discharged, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback